Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.32
-0.10 (-0.43%)
At close: Apr 28, 2026, 4:00 PM EDT
23.29
-0.03 (-0.13%)
After-hours: Apr 28, 2026, 6:09 PM EDT
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 34, with a low estimate of 29 and a high estimate of 36. The average target predicts an increase of 45.80% from the current stock price of 23.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $37 → $35 | Buy | Maintains | $37 → $35 | +50.09% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $34 → $35 | Strong Buy | Maintains | $34 → $35 | +50.09% | Feb 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $30 → $35 | Strong Buy | Maintains | $30 → $35 | +50.09% | Feb 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $34 | Strong Buy | Maintains | $30 → $34 | +45.80% | Feb 26, 2026 |
| Needham | Needham | Strong Buy Maintains $31 → $36 | Strong Buy | Maintains | $31 → $36 | +54.37% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
507.13M
from 376.07M
Increased by 34.85%
Revenue Next Year
656.20M
from 507.13M
Increased by 29.39%
EPS This Year
0.29
from -0.13
EPS Next Year
1.20
from 0.29
Increased by 319.56%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 538.3M | 737.2M | ||||||
| Avg | 507.1M | 656.2M | ||||||
| Low | 478.2M | 611.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 43.1% | 45.4% | ||||||
| Avg | 34.8% | 29.4% | ||||||
| Low | 27.2% | 20.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.56 | 1.69 | ||||||
| Avg | 0.29 | 1.20 | ||||||
| Low | 0.08 | 0.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 491.0% | ||||||
| Avg | - | 319.6% | ||||||
| Low | - | 143.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.